[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641350":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":11,"centralContacts":43,"locations":49,"responsibleParty":86,"collaborators":11,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":11,"eligibilityCriteria":94,"healthyVolunteers":90,"sex":95,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":11,"studyType":101,"phases":102,"briefSummary":104,"conditions":105,"keywords":11,"overallStatus":107,"whyStopped":11,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",[8,14,18,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment group A: HRS-4729 Injection","EXPERIMENTAL",null,[13],"Drug: HRS-4729 Injection",{"label":15,"type":10,"description":11,"interventionNames":16},"Treatment group B: HRS9531 Injection",[17],"Drug: HRS9531 Injection",{"label":19,"type":20,"description":11,"interventionNames":21},"Treatment group C: HRS-4729 Injection Placebo","PLACEBO_COMPARATOR",[22],"Drug: HRS-4729 Injection Placebo",{"label":24,"type":20,"description":11,"interventionNames":25},"Treatment group D: HRS9531 Injection Placebo",[26],"Drug: HRS9531 Injection Placebo",[28,33,37,40],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"DRUG","HRS-4729 Injection","HRS-4729 Injection; high dose, low dose",[9],{"type":29,"name":34,"description":35,"armGroupLabels":36,"otherNames":11},"HRS9531 Injection","HRS9531 Injection; high dose, low dose",[15],{"type":29,"name":38,"description":38,"armGroupLabels":39,"otherNames":11},"HRS-4729 Injection Placebo",[19],{"type":29,"name":41,"description":41,"armGroupLabels":42,"otherNames":11},"HRS9531 Injection Placebo",[24],[44],{"name":45,"role":46,"phone":47,"phoneExt":11,"email":48},"Mengshan Ni","CONTACT","+86-0518-81220121","mengshan.ni.mn1@hengrui.com",[50,70],{"facility":51,"status":11,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Beijing Tsinghua Changgung Hospital","Beijing","Beijing Municipality","102218","China","CN",{"type":58,"coordinates":59},"Point",[60,61],116.39723,39.9075,{"lat":61,"lon":60},[64,68],{"name":65,"role":46,"phone":66,"phoneExt":11,"email":67},"Lai Wei","+86-010-68322662","Weelai@163.com",{"name":65,"role":69,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":71,"status":11,"city":72,"state":73,"zip":74,"country":55,"countryCode":56,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"The First Affiliated Hospital of Zhengzhou University","Zhengzhou","Henan","450052",{"type":58,"coordinates":76},[77,78],113.64861,34.75778,{"lat":78,"lon":77},[81,85],{"name":82,"role":46,"phone":83,"phoneExt":11,"email":84},"Zujiang Yu","+86-0371-6691694","johnyuem@zzu.edu.cn",{"name":82,"role":69,"phone":11,"phoneExt":11,"email":11},{"type":87,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100641350","phase-2-a-study-of-hrs-4729-injection-and-hrs9531-injection-in-participants-with-metabolic-dysfunction-associated-steatohepatitis-100641350",false,"NCT07660848","A Study of HRS-4729 Injection and HRS9531 Injection in Participants With Metabolic Dysfunction-Associated Steatohepatitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Master Protocol Clinical Trial to Investigate the Efficacy and Safety of HRS-4729 Injection and HRS9531 Injection in Adult Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent\n2. Participants must have histologic diagnosis of MASH by liver biopsy\n3. Have liver fat content ≥8%\n4. Participants must have a body mass index (BMI) ≥24 kilograms per square meter (kg\u002Fm²) and ≤40 kg\u002Fm² with stable body weight for at least 3 months\n\nExclusion Criteria:\n\n1. Model for End-Stage Liver Disease (MELD) score \\> 12, or Child-Pugh (CTP) score \\> 6\n2. Known or suspected history of excessive alcohol consumption or alcohol dependence within 12 months prior to screening\n3. History of liver cirrhosis and\u002For liver decompensation, including but not limited to ascites, hepatic encephalopathy, esophageal or gastric variceal bleeding, etc.\n4. Previous or current liver disease due to other causes, including but not limited to: alcoholic steatohepatitis (ASH), drug-induced liver injury (DILI), viral hepatitis, autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), hereditary hepatobiliary diseases (e.g., hemochromatosis, α1-antitrypsin deficiency, Wilson's disease, etc.), occupational toxic liver disease, known or suspected hepatocellular carcinoma (HCC), etc.\n5. History of or planned organ transplantation (e.g., liver transplant) or bone marrow transplantation during the study period\n6. Use of GLP-1 receptor agonists (including multi-target drugs or compound preparations containing GLP-1 receptor agonists) within 3 months prior to screening, or previous discontinuation of GLP-1 receptor agonists due to safety\u002Ftolerance reasons\n7. Known or suspected hypersensitivity to GLP-1 and\u002For GIP and\u002For GCG receptor agonists and\u002For their excipient","ALL","18 Years","75 Years",{"count":99,"type":100},160,"ESTIMATED","INTERVENTIONAL",[103],"PHASE2","The purpose of this study is to investigate the efficacy and safety of HRS-4729 injection and HRS9531 injection in adult participants with metabolic dysfunction-associated steatohepatitis after 52 weeks of treatment.",[106],"Metabolic Dysfunction-Associated Steatohepatitis (MASH)","NOT_YET_RECRUITING","2026-06-16",{"date":110,"type":111},"2026-06-22","ACTUAL",{"date":113,"type":100},"2026-07",{"date":115,"type":100},"2028-07",{"name":5,"class":6},2]